Survival analyses, in early-stage (stage I and II) and advanced-stage (stage III and IV) group of CRC patients respectively, demonstrated that TSP50 overexpression was associated with shortened disease-specific survival for patients with early-stage CRC (log-rank P = 0.004; Figure 5C), but not for patients with advanced stage (log-rank P = 0.274; Figure 5D). Here, PRSS50 is linked to colorectal carcinoma.